What Intuitive Surgical Bears Saw Before The Fall

If you only read the Q2 2026 headlines, Intuitive Surgical looked like a win. Revenue and net income were higher, and margins were healthier than a year earlier. Holding Intuitive Surgical from the start of the year would have meant a 22.9% loss, including dividends. If you had been weighing a position on 1 January 2026, how much of that gap between business results and share performance was already visible on the record?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Intuitive Surgical has already moved. Pinpoint other ways to investigate the theme among 92 robotics and automation stocks.

The Two Stories Investors Had To Choose Between On Intuitive Surgical

The shares cost US$566 at the start of the period, so anyone looking at Intuitive Surgical then had to judge whether that price better matched an optimistic or cautious story.

The bullish narrative put fair value at US$685, or 21% above the start price. It leaned on faster da Vinci 5 adoption, with early upgrades, stronger recurring revenue, and digital tools turning the platform into a data rich surgical operating system.

The bearish view set fair value at US$350, or 38% below the start price. It focused on rising healthcare cost controls and tariffs, which were expected to squeeze pricing power and push gross margins lower over time.

What The Results Changed For The Intuitive Surgical Thesis

The key fact was Q2 2026 delivery. Intuitive Surgical reported revenue of US$2.89b and net income of US$818.1m, with net margin at 28.3%. That combination supported the optimistic story that the business could sustain healthy profitability. The same period still gave the cautious case fresh support, with FDA alerts, stapler recalls, tariffs, and hospital budget pressure all weighing on sentiment. Overall, the evidence cut both ways.

The lesson is simple. When a thesis hinges on margins, do not just track growth headlines. Watch the reported net margin and the specific cost line investors are worried about, such as tariffs or reimbursement changes, and check whether those actually move the percentage.

What Intuitive Surgical’s Lower Price Is Asking You To Believe

Intuitive Surgical now trades at US$433, after the share price fell 22.9% from the start of the year. The selected Narrative still places its Fair Value above that level, based on a view that the business model and user ecosystem justify paying more than today’s quote.

Instead of focusing on headlines, this Narrative leans on the installed da Vinci base, high procedure volumes, and a heavy tilt toward recurring instrument, service, and software revenue. For that higher Fair Value to be reached, buyers today would need the procedure driven, high margin ecosystem to keep scaling on top of the existing systems.

"A Growing Installed Base is good but the Recurring Revenue makes the Difference. Today, 9,539 da Vinci systems are installed worldwide, with an annual growth rate of 15.1%. Each year, these systems perform approximately 2.2 million procedures, a number that has been growing at a rate of 22.2% per year."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Looking Beyond Intuitive Surgical

Intuitive Surgical turns surgical precision into recurring use of its systems. You can also look one step earlier in a patient's journey.

Before a robot enters the theatre, someone needs a diagnosis. That means lab tests, point of care checks, and rapid screens confirming what treatment is needed.

Another large healthcare group focuses on this testing backbone. It builds tools that help clinicians spot chronic disease, track infections, and monitor nutrition.

As hospitals widen access to screening and monitoring, the demand picture shifts. A diagnostics heavyweight must adapt when early detection becomes the expectation, not the exception.

One Narrative has already put a figure on it. → Uncover the company trading 13% below one Narrative's Fair Value

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com